Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026
PR Newswire•29/10/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $1.13 billion, up 4.2% from Q3 2025
- ➤Q3 non-GAAP diluted EPS excluding tariff refunds $1.44
- ➤Fiscal 2026 revenue guidance raised to $4.64-$4.66 billion
- ➤Fiscal 2026 non-GAAP EPS guidance raised to $5.40-$5.45
- ➤Q3 operating cash flow $419 million, up from $284 million
Expert Statements
Jacob Thaysen, Chief Executive Officer of Illumina
“In the third quarter, healthy clinical demand and robust NovaSeq X placements drove results above our guidance. Based on continued momentum, we are raising our full year revenue and earnings guidance.”
Jacob Thaysen, Chief Executive Officer of Illumina
“As we continue to execute our strategy, our innovation is broadening the value of the Illumina ecosystem. Together with our customers, we are laying the foundation for AI to transform our understanding of human biology and improve patient outcomes.”
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026 PR Newswire
SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2026.
Get started
Create a free account to read the full story.